Therapeutics News and Research

RSS

EntreMed third quarter net loss decreases to $1.3 million

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported financial results for the three and nine-month periods ending September 30, 2011.

14 Nov 2011

Positive results from Oncolytics REOLYSIN combination Phase 2 clinical trial for head and neck cancers

Oncolytics Biotech Inc. today announced that positive results from a Phase 2 clinical trial (REO 015) using intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

14 Nov 2011

Nile Therapeutics third quarter net loss decreases to $1.1 million

Nile Therapeutics, Inc., a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced its third quarter financial results for 2011.

14 Nov 2011

Six-month results from BIOTRONIK's PRO-Kinetic Energy stent study presented at TCT 2011

BIOTRONIK AG announced that the six-month results of the ENERGY Registry were presented last week by Prof. Raimund Erbel at the Transcatheter Cardiovascular Therapeutics (TCT 2011) conference.

14 Nov 2011

Scientists discover molecular basis for tamoxifen resistance and potential way to defeat it

In the last three decades, thousands of women with breast cancer have taken the drug tamoxifen, only to discover that the therapy doesn't work, either because their tumors do not respond to the treatment at all, or because they develop resistance to it over time. Now researchers at the University of California, San Francisco (UCSF) have discovered the molecular basis for tamoxifen resistance and found a potential way to defeat it.

14 Nov 2011

Scientists create new phenotypic cancer drug screening platform

Researchers have created a new phenotypic screening platform that better predicts success of drugs developed to prevent blood vessel tumor growth when moving out of the lab and onto actual tumors.

14 Nov 2011

Genzyme's alemtuzumab Phase lll trial on MS meets co-primary endpoints

Genzyme, a Sanofi company, reports today that the Phase lll CARE-MS ll trial met both of its co-primary endpoints. Relapse rate and sustained accumulation (worsening) of disability (SAD) were significantly reduced in multiple sclerosis patients receiving alemtuzumab as compared with Rebif.

14 Nov 2011

Next-generation drugs may prevent skin lesions in BRAF mutation-positive melanoma

Findings from preclinical studies in a skin cancer model showed that next-generation BRAF inhibitors used alone, or first-generation BRAF inhibitors used in combination with an epidermal growth factor receptor inhibitor, may have the potential to prevent drug-induced skin lesions in BRAF mutation-positive patients treated for melanoma.

14 Nov 2011

ZIOPHARM announces darinaparsin preclinical data on prostate cancer

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today that results from preclinical studies of darinaparsin (Zinapar or ZIO-101), a novel organic arsenic, in prostate cancer were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 12-16 in San Francisco.

14 Nov 2011

Combination of REGN910 and aflibercept inhibits tumor angiogenesis in animal models

Combining the investigational agents REGN910 and aflibercept yielded statistically significant improvements in antitumor effects in animal models compared with either agent alone, according to results presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, held Nov. 12-16, 2011.

14 Nov 2011

Amplification of ALK gene may drive rapid breast cancer metastasis

Amplification of anaplastic lymphoma kinase, which has been reported in other cancers such as non-small cell lung cancers, may be a primary driver of the rapid metastasis that patients with inflammatory breast cancer experience.

14 Nov 2011

Researchers show how ER-positive breast cancer tumors become resistant to tamoxifen

Researchers have shown how estrogen receptor-positive breast cancer tumors become resistant to tamoxifen, the only approved hormonal therapy for premenopausal patients with this type of breast cancer.

14 Nov 2011

Exelixis reports cabozantinib phase 2 trial data on bone metastases

Exelixis, Inc. today reported interim data on pain relief and related reduction in narcotic analgesic use with cabozantinib in castration-resistant prostate cancer (CRPC) patients with bone metastases.

14 Nov 2011

New data on TetraLogic's TL32711 cancer drug to be presented at AACR-NCI-EORTC conference

TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced presentations of new data on its Smac mimetic drug candidate TL32711 at the 2011 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics in San Francisco.

14 Nov 2011

Patients with KRAS mutant NSCLC should respond well to antifolates

Patients with non-small cell lung cancer who have mutations in the KRAS gene should respond well to the antifolate class of drugs, according to results of a recent study conducted by Quintiles comparing human lung cancer cell lines and patients.

14 Nov 2011

Renowned cardiologist wins TCT 2011 Geoffrey O. Hartzler Master Clinical Operator Award

Horst Sievert, MD, PhD, a renowned interventional cardiologist, was presented the TCT 2011 Geoffrey O. Hartzler Master Clinical Operator Award in a ceremony held today during the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

14 Nov 2011

NovaUCD to showcase 15 new high-tech ventures at annual start-up awards

NovaUCD will showcase 15 new high-tech and knowledge-intensive ventures emerging from University College Dublin (UCD) research programmes during its annual start-up awards evening next week.

13 Nov 2011

NeoStem third quarter revenues increase to $17.8 million

NeoStem, Inc., an international biopharmaceutical company with a focus on cell based therapeutics development, today reported third quarter results and recent progress in its business.

11 Nov 2011

Elixir Medical announces initiation of DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System study

Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced enrollment initiation for a 120-patient, international pivotal clinical study to evaluate the safety and efficacy of the DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System designed to resorb in the body within 1 to 2 years after implantation and return the patients' coronary vessel to de novo state.

11 Nov 2011

Worm model to evaluate drugs for Parkinson's disease

Researchers at The University of Texas at Austin have devised a simple test, using dopamine-deficient worms, for identifying drugs that may help people with Parkinson's disease.

11 Nov 2011

Therapeutics News and Research

EntreMed third quarter net loss decreases to $1.3 million

Positive results from Oncolytics REOLYSIN combination Phase 2 clinical trial for head and neck cancers

Nile Therapeutics third quarter net loss decreases to $1.1 million

Six-month results from BIOTRONIK's PRO-Kinetic Energy stent study presented at TCT 2011

Scientists discover molecular basis for tamoxifen resistance and potential way to defeat it

Scientists create new phenotypic cancer drug screening platform

Genzyme's alemtuzumab Phase lll trial on MS meets co-primary endpoints

Next-generation drugs may prevent skin lesions in BRAF mutation-positive melanoma

ZIOPHARM announces darinaparsin preclinical data on prostate cancer

Combination of REGN910 and aflibercept inhibits tumor angiogenesis in animal models

Amplification of ALK gene may drive rapid breast cancer metastasis

Researchers show how ER-positive breast cancer tumors become resistant to tamoxifen

Exelixis reports cabozantinib phase 2 trial data on bone metastases

New data on TetraLogic's TL32711 cancer drug to be presented at AACR-NCI-EORTC conference

Patients with KRAS mutant NSCLC should respond well to antifolates

Renowned cardiologist wins TCT 2011 Geoffrey O. Hartzler Master Clinical Operator Award

NovaUCD to showcase 15 new high-tech ventures at annual start-up awards

NeoStem third quarter revenues increase to $17.8 million

Elixir Medical announces initiation of DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System study

Worm model to evaluate drugs for Parkinson's disease

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News